The addition of pembrolizumab to standard chemotherapy with a platinum-based drug and pemetrexed resulted in improved overall survival, progression-free survival, and tumor response rate among patients with previously untreated metastatic nonsquamous, non–small cell lung cancer without sensitizing epidermal growth factor receptor or anaplastic lymphoma kinase mutations in this double-blind, phase 3 trial.